Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels

Expert Opinion on Biological Therapy

Volumn 13, Issue 9, 2013, Pages 1335-1341

  Yalcin, Arzu Didem ^a,b   Cilli, Aykut ^c   Bisgin, Atil ^d   Strauss, Ludwig G ^e   Herth, Felix ^f  

^a ANTALYA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c AKDENIZ UNIVERSITY   (Turkey)

^d LINKÖPING UNIVERSITY   (Sweden)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

25 hydroxyvitamin D; Asthma; Cardiovascular risk; CXCL8; IL 1 ; Omalizumab; Protein C and S deficiency; SCD200

Indexed keywords

25 HYDROXYVITAMIN D; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CD200 ANTIGEN; CLOPIDOGREL; CYTOKINE; D DIMER; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EOSINOPHIL CATIONIC PROTEIN; FLUTICASONE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 8; NITRIC OXIDE; OMALIZUMAB; PROTEIN C; PROTEIN S; SALMETEROL; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; ARTICLE; ASTHMA; BLOOD SAMPLING; BRAIN EMBOLISM; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EXERCISE TEST; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MALE; MITRAL VALVE PROLAPSE; MITRAL VALVE REPLACEMENT; PILOT STUDY; PRICK TEST; PROTEIN BLOOD LEVEL; PROTEIN C DEFICIENCY; PROTEIN EXPRESSION; PROTEIN S DEFICIENCY; REMISSION; RHEUMATOID ARTHRITIS; RISK FACTOR; SKIN PRICK TEST; VENOUS THROMBOEMBOLISM;

EID: 84881535508     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.819338     Document Type: Article

References (31)

1. Kim B, Eggel A, Tarchevskaya SS, et al. Accelerated disassembly of IgE-receptor complexes by a disruptive macromolecular inhibitor. Nature 2012; 491(7425): 613-17
2. Yalcin AD, Bisgin A. Anti-IgE therapy in severe allergic conditions. J Allergy Ther 2012; 3: 120
3. Yalcin AD, Bisgin A, Gorczynski RM. IL-8, IL10, TGF-b and GCSF levels were increased in severe persistent allergic asthma patients with the anti-IgE treatment. Mediators Inflamm 2012; 2012: 720976
4. Yalcin AD, Gumuslu S, Parlak GE, et al. Systemic levels of ceruloplasmin oxidase activity in allergic asthma and allergic rhinitis. Immunopharmacol Immunotoxicol 2012; 34(6): 1047-53
5. Yalcin AD, Bisgin A. The relation of sTRAIL levels and quality of life in omalizumab using severe persistent allergic asthma patients. (WISC 2012: WAO Outstanding Abstract Award). Med Sci Monit 2012; 18(8): LE9-10
6. Chang TW. Developing antibodies for targeting immunoglobulin and membrane bound immunoglobulin E. Allergy Asthma Proc 2006; 27: S7-S14 (Pubitemid 43700848)
7. Chang TW, Shiung YY. Anti IgE as a mast cell stabilizing therapeutic agent. J Allergy Clin Immunol 2006; 117: 1203-12 (Pubitemid 43795763)
8. Adcock LM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008; 372(9643): 1073-87
9. Heaney GL, Robinson DS. Severe asthma treatment: need for characterising patients. Lancet 2005; 365(9463): 974-6 (Pubitemid 41071432)
10. Eisner MD, Zazzali JL, Miller MK, et al. Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study. J Asthma 2012; 49(6): 642-8
11. Long AA, Fish JE, Rahmaoui A, et al. Baseline characteristics of patients enrolled in EXCELS: a cohort study. Ann Allergy Asthma Immunol 2009; 103(3): 212-19
12. Ali AK, Hartzema AG. Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting. J Asthma Allergy 2012; 5: 1-9
13. Farrell RJ, Lamb J. Prophylactic anticoagulation in heterozygous protein C deficiency. Lancet 1993; 341(8847): 754 (Pubitemid 23085203)
14. Harper PL, Edgar PF, Luddington RJ, et al. Protein C deficiency and portal thrombosis in liver transplantation in children. Lancet 1988; 2(8617): 924-7
15. Koduri G, Norton S, Young A, et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford) 2010; 49: 1483-9
16. Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000; 18: 157-62 (Pubitemid 30091174)
17. Anderson WJ, Short PM, Williamson PA, et al. Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial. Chest 2012; 142(6): 1553-61
18. Kim CK. Eosinophil-derived neurotoxin: a novel biomarker for diagnosis and monitoring of asthma. Korean J Pediatr 2013; 56(1): 8-12
19. Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Bodzenta-Lukaszyk A. Airway inflammation and eotaxin in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy. Adv Med Sci 2011; 56(2): 318-22
20. Taylor DR, Pijnenburg MW, Smith AD, et al. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006; 61: 817-27 (Pubitemid 44369409)
21. Eisner MD, Yegin A, Trzaskoma B, et al. Severity of asthma score predicts clinical outcomes in patients with moderate to severe persistent asthma severity of asthma score predicts outcomes. Chest 2012; 141(1): 58-65
22. Gershon AS, Victor JC, Guan J, et al. Pulmonary function testing in the diagnosis of asthmapulmonary function testing in asthma diagnosis: a population study. Chest 2012; 141(5): 1190-6
23. Scott S, Currie J, Albert P, et al. Risk of misdiagnosis, health-related quality of life, and BMI in patients who are overweight with doctor-diagnosed asthmaquality of life in obese patients with asthma. Chest 2012; 141(3): 616-24
24. Global Initiative for Asthma: GINA Report, Global Strategy for Asthma Management and Prevention - updated. 2012. Available from: www.ginasthma.org
25. Krause K, Metz M, Makris M, et al. The role of interleukin-1 in allergy-related disorders. Curr Opin Allergy Clin Immunol 2012; 12(5): 477-84
26. Yalcin AD, Karakas AA, Soykam G, et al. A case of toxic epidermal necrolysis with diverse etiologies: successful treatment with intravenous immunoglobulin and pulse prednisolone and effects on sTRAIL and sCD200 levels. Clin Lab 2013; 59: 681-5
27. Gorczynski RM. CD200: CD200Rmediated regulation of immunity. ISRN Immunol 2012; doi: 10.5402/2012/682168
28. Korn S, Hübner M, Jung M, et al. Severe and uncontrolled adult asthma is associated with vitamin D insufficiency and deficiency. Respir Res 2013; 14(1): 25
29. Chambers ES, Nanzer AM, Richards DF, et al. Serum 25-dihydroxyvitamin D levels correlate with CD4(+)Foxp3(+) T-cell numbers in moderate/severe asthma. J Allergy Clin Immunol 2012; 130(2): 542-4
30. Yalcin AD, Bisgin A, Cetinkaya R, et al. Clinical course and side effects of omalizumab in patients with severe persistent asthma. Clin Lab 2013; 59: 71-7
31. Yalcin AD, Ucar S, Gumuslu S, Strauss L. Effects of omalizumab on eosinophil cationic peptid, 25-hydroxyvitamin-D, IL-1beta, and sCD200 in a cases of samter's syndrome: 36 months follow-up. Immunopharmacol Immunotoxicol 2013; 35(4): 524-7